CF
GALT icon

Centaurus Financial’s Galectin Therapeutics GALT Stock Holding History

Centaurus Financial’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,732
Closed -$23K – 919
2022
Q4 		$23K Hold
20,732
– – ﹤0.01% 832
2022
Q3 		$34K Sell
20,732
-215
-1% -$402 ﹤0.01% 841
2022
Q2 		$27K Sell
20,947
-167
-0.8% -$240 ﹤0.01% 825
2022
Q1 		$34K Buy
+21,114
New +$40.9K ﹤0.01% 884
2021
Q4 		– Sell
-22,614
Closed -$88K – 944
2021
Q3 		$88K Buy
22,614
+7,000
+45% +$23.7K 0.01% 872
2021
Q2 		$50K Hold
15,614
– – ﹤0.01% 885
2021
Q1 		$34K Hold
15,614
– – ﹤0.01% 807
2020
Q4 		$35K Hold
15,614
– – ﹤0.01% 769
2020
Q3 		$42K Hold
15,614
– – 0.01% 638
2020
Q2 		$48K Buy
15,614
+413
+3% +$1.04K 0.01% 610
2020
Q1 		$30K Sell
15,201
-62
-0.4% -$151 0.01% 517
2019
Q4 		$44K Hold
15,263
– – 0.01% 625
2019
Q3 		$56K Sell
15,263
-1,300
-8% -$4.7K 0.01% 439
2019
Q2 		$69K Buy
16,563
+16,481
+20,099% +$71.4K 0.01% 585
2019
Q1 		$16.1K Buy
+82
New +$394 0.09% 188
2018
Q4 		– Sell
-10
Closed -$60 – 496
2018
Q3 		$60 Sell
10
-16,702
-100% -$91.9K 0.01% 530
2018
Q2 		$106K Buy
16,712
+6,712
+67% +$32.7K 0.01% 688
2018
Q1 		$47K Hold
10,000
– – 0.01% 452
2017
Q4 		$33K Buy
+10,000
New +$25.3K 0.01% 318

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Centaurus Financial's GALT Position: Q1 2023 in Review

Centaurus Financial sold out of Galectin Therapeutics (GALT) in Q1 2023, closing a stake of 20,732 shares — an estimated $23K sold.

Centaurus Financial first reported a position in GALT in Q4 2017 and held it in 19 quarters. The position peaked at $106K in Q2 2018. 60 funds tracked by Wall St. Rank hold GALT as of Q1 2023.

  • Centaurus Financial reported no remaining Galectin Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Centaurus Financial sold 20,732 Galectin Therapeutics shares in Q1 2023, an estimated $23K.
  • Centaurus Financial first reported a position in Galectin Therapeutics in Q4 2017 and held it in 19 quarters.
  • Centaurus Financial's Galectin Therapeutics position peaked at $106K in Q2 2018.
  • 60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2023.

Based on Centaurus Financial's 13F filing for Q1 2023, filed 18 May 2023.